By disrupting the interaction with KEAP1-E3 ubiquitin ligase, accumulated and dysregulated NRF2 may contribute to tumor development and chemoresistance, suggesting that inhibiting NRF2 is a promising strategy for cancer therapeutics. This evidence concerns the gene KEAP1 and cancer.